. First phase 3 trial of GLP-1 receptor agonist for neurodegeneration. Lancet. 2025 Feb 4; Epub 2025 Feb 4 PubMed.

Recommends

Please login to recommend the paper.

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.